Ron Goldberg

The researchers conducted a retrospective cohort study using claims data from the Optum Research Database for 538 patients at least 6 years of age who initiated mepolizumab treatment for asthma between January 2016 and December 2019.

The researchers analyzed 351,870 US patients at least 12 years of age from the IBM MarketScan databases who received SABA for asthma from 2010 to 2017.

The primary endpoint was time from baseline to azelastine’s onset of the usefulness, which researchers assessed by comparing azelastine and placebo with respect to the change from baseline in total nasal symptom score.

Greater disease burden in chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with increased loss of smell severity. Outcomes of CRSwNP were significantly improved with dupilumab, regardless of loss of smell severity at baseline. These are among the post-hoc analysis findings presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific…

Investigators assessed a real-world pediatric patients with asthma who used biologic therapy to identify their response to prescribed biologics and reasons for discontinuation of therapy as well as to characterize other attributes of this population.

Investigators found the association between food allergy at 3 to 5 years of age and the risk of ever having asthma by 10 years of age was significantly modified by having atopic dermatitis.

Meaningful improvement was defined as an ACT score greater than or equal to 20 or an increase of at least 3 units at 6 months from the ACT baseline score.

The primary outcome was to compare dupilumab, benralizumab, and mepolizumab in patients with at least 2 pre-index exacerbations.

The study included 223 patients with moderate-severe disease based on baseline scores.

“A needle-free option for administering epinephrine would be used more quickly after symptoms developed and would be easier to use versus an injectable device.”